Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the EGFR and the PKB pathway in cancer.

Current opinion in cell biology - 1 Apr 2009

Klein Shoshana, Levitzki Alexander

Abstract excerpt

The EGFR and PKB pathways are frequently activated in cancer, so are prime targets for cancer therapy. To this end, new inhibitors are being tested. EGFR inhibitors as single therapy have little benefit, although therapies that evoke an antitumor immune response are more effective. Resistance mut...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Isoenzymes
Share to Neoplastic Stem Cells
Share to Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Adenosine Triphosphate

Share to Clinical Trials as Topic

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to PTEN Phosphohydrolase

Source

Identifiers

PMID: 19216065
DOI: 10.1016/j.ceb.2008.12.006

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19216065-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the EGFR and the PKB pathway in cancer.PMID 19216065Read ↗

Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?Semantic proximity Read ↗

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trialsSemantic proximity Read ↗

Targeted Therapies in Cancer: To Be or Not to Be, SelectiveSemantic proximity Read ↗

Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor.Semantic proximity Read ↗

Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.Semantic proximity Read ↗

Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapySemantic proximity Read ↗

The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated ReviewSemantic proximity Read ↗

EGFR antagonists in cancer treatment.Semantic proximity Read ↗

Current State and Future Challenges for PI3K Inhibitors in Cancer TherapySemantic proximity Read ↗

RAS/RAF/MEK Inhibitors in OncologySemantic proximity Read ↗

Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.